These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 33349107)
1. Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature. Joshi G; Wilens T; Firmin ES; Hoskova B; Biederman J J Psychopharmacol; 2021 Mar; 35(3):203-210. PubMed ID: 33349107 [TBL] [Abstract][Full Text] [Related]
2. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis. Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025 [TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder in Individuals with Autism Spectrum Disorder. Joshi G; Wilens TE Child Adolesc Psychiatr Clin N Am; 2022 Jul; 31(3):449-468. PubMed ID: 35697395 [TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy of Attention Deficit Hyperactivity Disorder Symptom Profile in ASD. Naguy A J Nerv Ment Dis; 2017 Sep; 205(9):738. PubMed ID: 28846573 [No Abstract] [Full Text] [Related]
5. Effects of Atomoxetine in Individuals with Attention-Deficit/Hyperactivity Disorder and Low-Functioning Autism Spectrum Disorder. Kilincaslan A; Mutluer TD; Pasabeyoglu B; Tutkunkardas MD; Mukaddes NM J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):798-806. PubMed ID: 27228116 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of pharmacological interventions for managing ADHD symptoms in individuals with autism spectrum disorder: A systematic review and meta-analysis. Martins PLB; Torquato GCP; Dias GAPF; Leite IB; Gaspar TM; Pinto JP; Macedo DS Prog Neuropsychopharmacol Biol Psychiatry; 2024 Aug; 134():111089. PubMed ID: 39004333 [TBL] [Abstract][Full Text] [Related]
7. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis. Elliott J; Johnston A; Husereau D; Kelly SE; Eagles C; Charach A; Hsieh SC; Bai Z; Hossain A; Skidmore B; Tsakonas E; Chojecki D; Mamdani M; Wells GA PLoS One; 2020; 15(10):e0240584. PubMed ID: 33085721 [TBL] [Abstract][Full Text] [Related]
8. Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder. Jain R; Katic A Prim Care Companion CNS Disord; 2016 Aug; 18(4):. PubMed ID: 27828696 [TBL] [Abstract][Full Text] [Related]
9. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder. Handen BL; Aman MG; Arnold LE; Hyman SL; Tumuluru RV; Lecavalier L; Corbett-Dick P; Pan X; Hollway JA; Buchan-Page KA; Silverman LB; Brown NV; Rice RR; Hellings J; Mruzek DW; McAuliffe-Bellin S; Hurt EA; Ryan MM; Levato L; Smith T J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):905-15. PubMed ID: 26506581 [TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology. Sikirica V; Findling RL; Signorovitch J; Erder MH; Dammerman R; Hodgkins P; Lu M; Xie J; Wu EQ CNS Drugs; 2013 Nov; 27(11):943-53. PubMed ID: 23975660 [TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Treatment Options for Preschoolers with Attention-Deficit/Hyperactivity Disorder. Wigal S; Chappell P; Palumbo D; Lubaczewski S; Ramaker S; Abbas R J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):104-118. PubMed ID: 31967914 [No Abstract] [Full Text] [Related]
12. Dose-Response Effects of Long-Acting Liquid Methylphenidate in Children with Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study. Kim SJ; Shonka S; French WP; Strickland J; Miller L; Stein MA J Autism Dev Disord; 2017 Aug; 47(8):2307-2313. PubMed ID: 28474229 [TBL] [Abstract][Full Text] [Related]
13. Commentary: Identifying individualized predictions of response in ADHD pharmacotherapy - a commentary on Rodrigues et al. (2020). Farhat LC; Bloch MH J Child Psychol Psychiatry; 2021 Jun; 62(6):701-703. PubMed ID: 33368287 [TBL] [Abstract][Full Text] [Related]
14. Clinical guidance on pharmacotherapy for the treatment of attention-deficit hyperactivity disorder (ADHD) for people with intellectual disability. Miller J; Perera B; Shankar R Expert Opin Pharmacother; 2020 Oct; 21(15):1897-1913. PubMed ID: 32692263 [TBL] [Abstract][Full Text] [Related]
15. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. May DE; Kratochvil CJ Drugs; 2010; 70(1):15-40. PubMed ID: 20030423 [TBL] [Abstract][Full Text] [Related]
16. Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis. Pan PY; Jonsson U; Şahpazoğlu Çakmak SS; Häge A; Hohmann S; Nobel Norrman H; Buitelaar JK; Banaschewski T; Cortese S; Coghill D; Bölte S Psychol Med; 2022 Jan; 52(1):14-25. PubMed ID: 34635194 [TBL] [Abstract][Full Text] [Related]
17. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry. Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742 [TBL] [Abstract][Full Text] [Related]
18. Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study. McCracken JT; McGough JJ; Loo SK; Levitt J; Del'Homme M; Cowen J; Sturm A; Whelan F; Hellemann G; Sugar C; Bilder RM J Am Acad Child Adolesc Psychiatry; 2016 Aug; 55(8):657-666.e1. PubMed ID: 27453079 [TBL] [Abstract][Full Text] [Related]
20. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up. Su Y; Yang L; Stein MA; Cao Q; Wang Y J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]